Hirudoid (Chondroitin Polysulfate)

Hirudoid is indicated for several superficial vascular and traumatic skin conditions where reduction of bruising, swelling, or clot formation is desired. It is applied directly to the affected area and may be used in conjunction with standard wound‑care measures.

• Bruising (contusions) caused by minor trauma, to help reduce discoloration and discomfort.
• Superficial thrombophlebitis of small veins, to limit clot propagation and inflammation.
• Hematoma formation following injury or surgical procedures, to support faster resolution.
• Contusion‑related swelling and pain, to improve mobility and comfort.
• Post‑procedural skin discoloration, to promote more uniform appearance.

• Chondroitin polysulfate exerts its topical antithrombotic and anti‑inflammatory activity by interfering with the coagulation cascade. When applied to the skin, it binds to fibrinogen and inhibits fibrin formation, reducing clot development. The compound also impairs platelet aggregation and modulates inflammatory mediators, leading to decreased edema and erythema in the treated tissue. Additionally, the glycosaminoglycan layer enhances microcirculatory flow by reducing local viscosity.

Topical application of Hirudoid may cause skin‑related reactions, most of which are mild and reversible. While most users experience only minor irritation, clinicians should be aware of less frequent but more serious cutaneous responses.

Common

• Mild erythema or redness at the application site.
• Itching or mild pruritus.
• Slight burning or stinging sensation.
• Localized dry skin or scaling.
• Transient discoloration of the skin.

Serious

• Severe allergic dermatitis with swelling and blistering.
• Contact urticaria or widespread rash.
• Systemic hypersensitivity reactions such as anaphylaxis (rare).

When using Hirudoid, certain precautions help minimize adverse reactions and ensure safe application.

• Do not apply to broken skin, open wounds, or mucous membranes.
• Avoid use on areas with known hypersensitivity to chondroitin polysulfate or other glycosaminoglycans.
• Keep the product out of reach of children; accidental ingestion may cause systemic effects.
• Discontinue use and seek medical advice if severe irritation or allergic signs develop.
• Do not combine with other topical anticoagulant preparations without professional guidance.
• Use caution in patients with bleeding disorders or those taking systemic anticoagulants.
• Pregnant or nursing individuals should consult a healthcare professional before use.

Hirudoid can interact with other agents that affect coagulation or skin integrity, requiring attention to concurrent therapies.

Avoid

• Other topical antithrombotic or anticoagulant gels (e.g., heparin cream).
• Strong topical corticosteroids that may mask irritation.
• Products containing high concentrations of alcohol or irritants that could increase skin damage.

Use with caution

• Systemic anticoagulants (warfarin, direct oral anticoagulants) due to additive bleeding risk.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) applied to the same area.
• Herbal or dietary supplements with anticoagulant properties (e.g., ginkgo, fish oil).
• Extensive skin disease (eczema, psoriasis) where barrier function is compromised.